Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

Life Sciences, Neurology, Neuroscience +14

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.8K citations · Full text

Medicine, Neurology, Neuroscience +10

Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

Claudia F. Lucchinetti, Wolfgang Br�ck, Joseph E. Parisi et al. · Annals of Neurology · 2000 · 3.3K citations

Life Sciences, Neurology, Pathology +17

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

Medicine, Neurology, Pharmacology +6